Lilly to sell California biomanufacturing plant
Eli Lilly has hired CBRE Group to sell its biomanufacturing plant in Vacaville, California, which it claims is one of the largest bulk API manufacturing facilities for recombinant microbial-based biopharmaceuticals in the US.
The site includes a 52-acre campus, with 28 acres available for future expansion. The 74,577 sq. ft., (6,927 sq. m.) facility includes a downstream processing building, capable of handling complex purification steps, analytical laboratories for raw materials, environmental monitoring and release testing and a mechanical workshop for equipment maintenance and calibration.
The intention to sell the site comes more than six months after the company closed a Puerto Rico manufacturing site and said its focus would move to its insulin and biologics pipeline.
